MedTrace Logo

A Study of Personalized Neoantigen Cancer Vaccines

NCT03794128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2020-09-11

No results posted yet for this study

Summary

The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.

Conditions

Interventions

PROCEDURE

Blood collection for research (next-generation sequencing [NGS])

Participants will have whole blood collected for next-generation sequencing (NGS).

PROCEDURE

Blood collection for research (HLA typing)

Participants will have whole blood collected for HLA typing.

Sponsors & Collaborators

  • Gritstone bio, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2020-01-17
Completion
2020-05-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03794128 on ClinicalTrials.gov